Literature DB >> 698976

Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT.

J T Isaacs, W D Heston, R M Weissman, D S Coffey.   

Abstract

The Dunning R-3327-H is a well-differentiated transplantable rat prostatic adenocarcinoma that contains both hormone-sensitive and -insensitive cells. The component composed of hormone-insensitive cells has been permitted to grow in a castrated male, and a new slow-growing, well-differentiated hormone-insensitive subline of the tumor has been established and designated R-3327-HI. In addition, a rapidly growing hormone-insensitive anaplastic tumor has been developed, R-3327-AT. These three tumor lines have been characterized, and their histological and biochemical profiles are compared.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 698976

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  27 in total

1.  Prostate cancer reduces endurance exercise capacity in association with reductions in cardiac and skeletal muscle mass in the rat.

Authors:  Peter J Esau; Elizabeth M Gittemeier; Alexander B Opoku-Acheampong; Korynne S Rollins; Dryden R Baumfalk; David C Poole; Timothy I Musch; Bradley J Behnke; Steven W Copp
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Nuclear protein as a prognostic factor of growth activity in prostatic adenocarcinoma.

Authors:  G R Dohle; J A Beekhuis; G J van Steenbrugge; F H Schröder; H J Tanke
Journal:  Urol Res       Date:  1996

3.  Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model.

Authors:  Danielle J McCullough; Linda M-D Nguyen; Dietmar W Siemann; Bradley J Behnke
Journal:  J Appl Physiol (1985)       Date:  2013-10-31

4.  The epithelial origin of a stromal cell population in adenocarcinoma of the rat prostate.

Authors:  W C Beckman; J L Camps; R M Weissman; S L Kaufman; S J Sanofsky; R L Reddick; G P Siegal
Journal:  Am J Pathol       Date:  1987-09       Impact factor: 4.307

5.  Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation.

Authors:  M Kager; T Spruss; M R Schneider; E von Angerer
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

6.  Effects of high-intensity training on prostate cancer-induced cardiac atrophy.

Authors:  Dryden R Baumfalk; Alexander B Opoku-Acheampong; Jacob T Caldwell; Alec L E Butenas; Andrew G Horn; Olivia N Kunkel; Steven W Copp; Carl J Ade; Timothy I Musch; Bradley J Behnke
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

7.  Platinum(II) complexes interfering with testicular steroid biosynthesis: drugs for the therapy of advanced or recurrent prostate cancers? Preclinical studies.

Authors:  Sabine Schertl; Rolf W Hartmann; Christine Batzl-Hartmann; Thilo Spruss; Anton Maucher; Erwin von Angerer; Claus D Schiller; Martin R Schneider; Ronald Gust; Helmut Schönenberger
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-06       Impact factor: 4.553

8.  Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy.

Authors:  G Yan; Y Fukabori; G McBride; S Nikolaropolous; W L McKeehan
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

9.  Analysis of changes in rat prostate carcinoma following hormone deprivation.

Authors:  W C Beckman; A L Jacokes; J L Camps; R L Cook; G P Siegal
Journal:  Am J Pathol       Date:  1987-09       Impact factor: 4.307

10.  Blood flow responses to mild-intensity exercise in ectopic vs. orthotopic prostate tumors; dependence upon host tissue hemodynamics and vascular reactivity.

Authors:  Emmanuel Garcia; Veronika G C Becker; Danielle J McCullough; John N Stabley; Elizabeth M Gittemeier; Alexander B Opoku-Acheampong; Dietmar W Sieman; Bradley J Behnke
Journal:  J Appl Physiol (1985)       Date:  2016-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.